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Background: Endometriosis is frequently associated with high levels of CA125. This marker is therefore not useful
for discriminating ovarian endometrioma from ovarian malignancy. The aim of this study was to establish a panel of
complementary biomarkers that could be helpful in the differential diagnosis between ovarian endometriosis or
other ovarian benign masses and ovarian cancer.
Methods: Blood samples from 50 healthy women, 17 patients with benign ovarian tumors, 57 patients with ovarian
endometrioma and 39 patients with ovarian cancer were analyzed and serum values were measured for the
following biomarkers: CA125, HE4 and CA72-4.
Results: Serum CA125 concentration was elevated in both patients with ovarian endometriosis and ovarian cancer
but not in patients with other benign ovarian masses. HE4 was never increased in patients with endometriosis or
benign masses whereas it was significantly higher in all patients with ovarian cancer (p < 0.05). A marked difference
in CA72-4 values was observed between women with ovarian cancer (67%) and those with endometriosis
(p < 0.05).
Conclusions: The results of the study suggest that HE4 and CA72-4 determination is the best approach to confirm
the benign nature of ovarian endometrioma in women with high CA125 levels.
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Endometriosis is a common chronic disease, present in
5-10% of women in reproductive age [1]. The disease,
characterized by the presence and growth of endometrial
tissue outside the uterine cavity, is often associated with
infertility and pelvic pain and it tends to recur [2,5].
Endometriosis can be diagnosed by clinical and ultra-
sound examinations (US) but the most accurate proced-
ure to confirm the diagnosis is laparoscopy that allows
visualization of lesions and histological confirmation [6].
Endometriosis is a benign disease but it shares several
characteristics with invasive cancer. Cancer antigen 125
(CA125) measurement is an important component in* Correspondence: mariagrazia.porpora@uniroma1.it
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reproduction in any medium, provided the orthe work-up of a woman with an adnexal mass [7]. How-
ever, CA125 is characterized by a low diagnostic specifi-
city, as abnormally high concentrations can be found in
malignancies of different origin including non-ovarian
gynecological cancer, such as endometrial, pancreatic,
lung, breast and colorectal cancer [8]. In patients with
endometriosis CA125 levels can be high. In fact, CA125
is the most extensively investigated and used peripheral
biomarker of endometriosis [9]. In addition, elevated
serum levels of CA125 are associated with non-
gynecological diseases such as tuberculosis, liver cirrhosis
and also in physiological conditions such as pregnancy
or different phases of the menstrual cycle [10,11]. Thus,
CA125 has a limited role in the differential diagnosis
between endometriosis and ovarian cancer due to the
lack of specificity [12]. Recently, the role of surgery for
the treatment of ovarian endometriosis in women withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient population characteristics
Diagnosis Mean age n Classification
Healthy 30 50




I II III IV
Endometriosis 36 57 - 6 26 25
FIGO STAGE
I II III IV
EOC 64 39 3 2 4 30
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http://www.ovarianresearch.com/content/6/1/44pregnancy desire has been criticized because of the fear of
ovarian health tissue damage [6,13,14]. In selected cases,
particularly in women undergoing assisted reproductive
techniques, it is mandatory rule out an ovarian malignancy
before ovarian stimulation and embryo-transfer [15].
Misdiagnosed ovarian cancer has been found in women
with suspected ovarian endometriosis [16,17].
Therefore identification of non-invasive and accessible
markers of epithelial ovarian carcinoma (EOC) is valu-
able. For this reason serum tumor markers are being
increasingly used for the differential diagnosis of adnexal
masses.
Recently, the human epididymis protein 4 (HE4) has
proved to be a promising marker for epithelial ovarian
cancer with higher specificity and sensitivity than CA125
in distinguishing malignant from benign pelvic masses
[18,19]. Particularly, measuring both HE4 and CA125
serum concentrations increases the accuracy of ovarian
cancer diagnosis and provides valuable information for
discriminating ovarian tumors from ovarian endome-
triotic cysts [20,21] or other gynecologic conditions [8].
However, an increased HE4 levels have been observed
also in other types of cancer, i.e. lung adenocarcinoma
[22] and in patients with impaired renal function [23].
Other biomarkers have been studied for clinical applica-
tion in EOC. Among these, cancer antigen 72–4 (CA72-4),
a glycoprotein, which increases in gastric, colon, breast and
ovarian adenocarcinomas, may be employed alone or in
combination with CA125 and HE4. CA72-4 is less sensitive
than CA125 for EOC, but it is not influenced by pregnancy
or the phase of menstrual cycle [24,25].
The aim of this study was to evaluate the role of those
biomarkers, which are usually elevated in patients with
EOC, that could be useful to confirm the nature of ovar-
ian cystic endometriosis or other benign ovarian masses.
Methods
From June 2012 to February 2013, 115 consecutive Italian
women (mean age: 35 years, range: 22–82) referred to
the Department of Gynecology, Obstetrics and Urology
at the University of Rome ”Sapienza” for the presence of
an adnexal mass detected at clinical and ultrasound ex-
aminations were enrolled in the study. Control group
consisted of 50 healthy women (mean age: 30 years,
range: 21–57) with clinical and US outcome negative
for ovarian masses.
Exclusion criteria included current hormonal therapy,
pregnancy, chronic diseases or other types of cancer.
Two patients were excluded from the study because they
were at the beginning of pregnancy. The study was part
of a study protocol approved by local Ethics Commit-
tees. All patients signed written informed consent to the
study. At enrolment, medical history was collected and
peripheral blood samples were drawn from all womenand immediately sent to the laboratory for analysis of
tumor markers. All groups underwent complete physical
and gynecological examination and transvaginal ultra-
sound (TVUS) with color Doppler imaging.
Women diagnosed with a pelvic mass subsequently
underwent surgery. Disease was confirmed by histopatho-
logical examination. The women were divided into the fol-
lowing 4 Groups:
Group 1: 50 healthy women (mean age: 30 years, range:
21–57) with clinical and US examinations negative for
ovarian masses.
Group 2: 17 patients with benign ovarian tumors (mean
age: 40 years, range: 20–74) with clinical and
instrumental diagnosis of benign adnexal disease. Mean
diameter of cysts was 57 ± 30.6 mm (range 20–110).
Histopathology confirmed mature teratoma in 6 patients
(35%) and simple serous cyst in 11 patients (65%).
Group 3: 57 patients with ovarian endometrioma (mean
age: 36 years, range: 23–48). Diagnosis of endometriosis
was achieved on the basis of medical history, clinical
and pelvic transabdominal and/or transvaginal US
examinations. Patients with indeterminate findings
underwent pelvic magnetic resonance imaging (MRI) to
confirm suspected endometriosis using the previously
described technique [26,27]. At laparoscopy, the disease
was staged according to the rASRM classification [28].
Mean diameter of endometriomas was 33 ± 18.9 mm
(range 10–80). One patient had both endometriosis and
an ovarian dermoid cyst.
Group 4: 39 patients with ovarian carcinoma (mean
age: 64 years, range: 28–91). Histology confirmed the
diagnosis and staging was made according to the
International Federation of Gynecology and Obstetrics
(FIGO)[29].
Population characteristics are summarized in Table 1.
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All sera were acquired following a standard collection
protocol. Briefly, samples were collected in a Red Top
Vacutainer, clotted 60–90 min and centrifuged for
10 min at 1300 × g. The serum fractions were aliquoted
and stored at −80°C until analysis.
CA125 determination
Lumipulse® G1200 CA125II is an assay system for the
quantitative measurement of CA125 in specimens based
on chemiluminescent enzyme immunoassay technology
(CLEIA) by a two-step sandwich method (Innogenetics-
Fujirebio, Belgium-Japan). This assay makes use of solid
phase and ALP-labeled monoclonal antibodies (OC125
and M11 respectively).
CA125 in specimens specifically binds to anti-CA125
monoclonal antibody immobilized on the particles
forming antigen-antibody immunocomplexes. The parti-
cles are then washed and rinsed in order to remove un-
bound materials. Alkaline phosphatase (ALP)-labeled
anti-CA125 monoclonal antibody specifically binds to
CA125 of the immunocomplexes. After a second wash,
substrate solution is added. AMPPD contained in the
substrate solution is dephosporylated by the catalysis of
ALP indirectly conjugated to the particles. A lumines-
cent signal is generated by the cleavage reaction of
dephosphorylated 3-(2′-spiroadamantyl)-4-methoxy-4-
(3″-phosphoryloxy)-phenyl-1,2-dioxetane (AMPPD) and
reflects the amount of CA125 in the sample. Normal
levels of CA125 were considered less than 35 U/mL.
HE4 determination
HE4 levels were determined using the HE4 enzymatic
immunoassay (EIA)(Fujirebio Diagnostics). The HE4
EIA is a solid phase, non competitive immunoassay
based upon the direct ”sandwich” technique using two
monoclonal antibodies, 2H5 and 3D8, directed against











Median(range) 2.7 (2.1 - 4)
ap-value < 0.05 vs Group 1 (healthy); bp-value < 0.05 vs Group 2 (Benign) and Groupor patient serum samples and standards were incubated
with biotinylated anti-HE4 monoclonal antibody 2H5
aliquots in streptavidin coatedmicrostrips. HE4 present
in standards or serum samples was adsorbed to the
streptavidin coatedmicrostrips by the biotinylated anti-
HE4 monoclonal antibody during the incubation period.
The strips were then washed and incubated with horse-
radish peroxidase (HRP) labeled anti-HE4 monoclonal
antibody 3D8. After washing, buffered substrate/chromo-
gen reagent was added to each well and the enzyme reac-
tion was allowed to proceed. During the enzyme reaction
a blue color developed if the antigen was present. The in-
tensity of the color was directly proportional to the
amount of HE4 present in the samples. According to the
manufacturer’s indications, normal values of HE4 were
considered less than 150 pmol/L.
CA72-4 assay
CA72-4 was detected utilizing a solid phase two-site
immunoradiometric ELSA- CA72-4 assay (Cisbio Bioassays,
France). Two monoclonal antibodies were prepared
against sterically remote antigenic sites on the TAG 72
molecule: the first was coated on the ELSA solid phase,
the second, radiolabeled with iodine 125, was used as
tracer. TAG 72 molecules present in the standards or the
samples to be tested were “sandwiched” between the two
antibodies. Following the formation of the coated anti-
body/antigen/ antibody sandwich, the unbound tracer was
easily removed by a washing step. The radioactivity bound
to the Elsa was proportional to the concentration of TAG
72 present in the sample. Normal levels of CA72-4 were
considered to be less than 3.8 U/mL.
Statistical analysis
Women were stratified by disease in four groups. In each
group, the median, range, mean, SD for serum CA125,
HE4and CA72-4 levels were determined. Mann–Whitney




13 (9–97) 38 (8–167)a 480 (8–46210)a,b
60.6 53.8 508.3
26.5 15.3 301.5
58 (30–125) 53 (26–98) 426 (48–850)a,b
2.7 3 39.8
0.32 0.98 45.1
2.8 (2.1 - 3.3) 2.7 (1.8 -6.2) 7 (1–112)a,b
3 (endometriosis); Group 4 (ovarian cancer).
Figure 1 Box and whisker plots representing median levels and
the interquartile range (box) of (A) CA125, (B) HE4 and (C) CA72-4
for each studied group. The dashed horizontal line represents the
cut-off level for each marker (CA125 = 35 U/mL; HE4 = 150 pmol/L;
CA72-4 = 3.8 U/mL). The y axis is a logarithmic scale. Group 1 = Healthy
women; Group 2 = Ovarian cyst; Group 3 = Endometriosis;
Group 4 = Epithelial Ovarian Cancer.
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10–transformed whisker-box plots were generated for
each marker by disease group. The diagnostic perfor-
mance of the markers was also expressed as sensitivity,
specificity, positive predictive values (PPV) and negative
predictive values (NPV) using the following cut-off values:
35 U/mL for CA125, 150 pmol/L for HE4, 3.8 U/mL for
CA72-4. Receiver operator characteristic (ROC) curves
were constructed and the areas under the curve (AUC)
with binomial exact 95% confidence intervals (95% CI)
were calculated. The method described by DeLong et al.
was used to calculate the difference between two AUCs
[30]. For all statistical comparisons, a level of P < 0.05 was
accepted as statistically significant. All statistical analyses
were performed using MedCalc v.12.2.1.0.
Results
Biomarker distribution
CA125, HE4 and CA72-4 serum marker levels were
evaluated in all groups (163 women). Results expressed
as mean, median and ranges are shown in Table 2.
All markers showed significant difference between
Group 1 and Group 2 and Group 4 (p < 0.05). HE4 and
CA72-4 were significantly higher in Group 4 than in all
the other groups (p < 0.05). CA125 was significantly
higher in Group 3 and Group 4 than in Group 1 and
Group 2 (p < 0.05). The distribution of marker levels for
each studied group is shown in Figure 1.
Tumor marker sensitivity and specificity in malignant and
benign disease
In Group 4, HE4 was increased in 89.7% (35/39) of cases,
in this group CA72-4 was elevated in 67% (26/39) of cases,
while CA125 was positive in 92% (36/39) of patients.
In Group 3, CA125 was elevated in 56.1% (32/57) of
cases and a slight but not statistically significant increase
of CA72-4 was observed in 7% (4/57) of patients.
HE4 correctly discriminated malignant from benign dis-
ease (Group 2 and Group 3 vs Group 4) with a sensitivity
and specificity of 87% and 100%, respectively. PPV and
NPV of HE4 were 100% and 96% respectively.
In patients with malignancy, CA125 showed a sig-
nificantly higher sensitivity than CA72-4 (90% vs 67%,
p < 0.001), but a lower specificity than CA72-4 (70% vsTable 3 Sensitivity, specificity, PPV and NPV of controls
and malignant vs benign cases for each marker
CA125 HE4 CA72-4
Sensitivity % 90 87 67
Specificity % 70 100 96
PPV 51 100 84
NPV 95 96 89
Cut-off levels: CA125 = 35 U/mL; HE4 = 150 pmol/L; CA72-4 =3.8 U/mL.
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and 89% for CA125 and CA72-4, respectively (Table 3).
Diagnostic accuracy
Diagnostic performance of the markers in discriminating
malignant from benign gynecologic conditions was veri-
fied using ROC analysis. The resultant accuracy (ROC
Area) values for HE4, CA125 and CA72-4 and their cor-
responding ROC curves are shown in Figure 2A. All theFigure 2 ROC curves of healthy women, patients with benign mass a
cancer for CA125, HE4 and CA72-4. (A) ROC curves of healthy women a
CA125, HE4 and CA72-4. HE4 AUC = 0.985; CA125 AUC = 0.921; CA72-4 AUC
the only one statistically significant (P = 0.012). (B) ROC curves of patients w
and CA72-4. HE4 AUC = 0.986; CA125 AUC = 0.883; CA72-4 AUC = 0.845.three markers showed good performance, with AUCs of
0.985, 0.921 and 0.843 for HE4, CA125 and CA72-4 re-
spectively. When the ROC analysis was performed for
endometriosis, AUCs were 0.986 for HE4, 0.883 for
CA125 and 0.845 for CA72-4 (Figure 2B).
Discussion
Endometriosis is a known cause of CA125 elevation and
represents a common gynecologic disorder in women ofnd patients with endometriosis versus patients with ovarian
nd patients with benign mass versus patients with ovarian cancer for
= 0.843c The overall difference in AUCs between HE4 and CA72-4 was
ith endometriosis versus patients with ovarian cancer for HE4, CA125
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endometriosis is made by clinical and imaging technique
examinations [31] and confirmed by surgery with histo-
logical examination [6]. Recently surgical treatment of
ovarian endometriosis in women desiring pregnancy has
been criticized because of the risk of ovarian healthy
tissue damage [13,14]. Therefore, in selected cases with
ovarian endometrioma treated by medical therapy or
undergoing assisted reproductive techniques (ART)
without prior surgery, a correct diagnosis is mandatory.
In these cases, the use of tumor markers with high sensi-
tivity and specificity could help to reduce the risk, even
small, of undetected ovarian cancer. In fact, there is a
recognized association between endometriosis and clear
cell, low-grade serous and endometrioid ovarian cancer
[32]. So far, very little is known about the underlying fac-
tors involved in the malignant progression of endometri-
osis. For more than two decades CA125 has been the
only marker employed in the diagnosis of EOC, but,
although overexpressed in more than 80% of ovarian
cancers, it lacks of specificity [33].
In the present study, we investigated the role of
serum CA125, HE4 and CA72-4 in the diagnostic
evaluation of ovarian endometrioma and adnexal mass.
In agreement with data reported in literature [19],
more than 50% of women with endometriosis expressed
high levels of CA125, confirming the low specificity of
this marker.
It was recently observed that HE4 rarely increases in
benign gynecologic conditions suggesting its comple-
mentary role to CA125 [18,19,25,34,35]. In women with
endometriosis, Moore et al. observed a marked differ-
ence between HE4 levels, which was increased only in
3% of cases, compared to CA125, which was elevated in
67% of cases [19]. Hamed et al. showed that serum HE4
and CA125 concentrations were significantly higher in
patients with ovarian cancer compared with levels ob-
served in patients with benign disease or healthy con-
trols. In their study CA125 and HE4 had high sensitivity
(90% vs 83.3%) and combining the two markers EOC
were correctly detected in 97% of cases [36]. Moreover
HE4 measurement, in healthy premenopausal women as
well as in women with endometriosis, can be carried out
at any phase of the menstrual cycle, and irrespective of
hormonal therapy, extending the benefits of HE4 use in
clinical practice [37,38]. However, HE4 overexpression
has been also observed in non-oncologic conditions such
as chronic kidney disease, which represents the most im-
portant known source of false-positive HE4 results [23].
In addition, recent studies have reported high HE4 levels
also in some benign gynecological conditions such as
uterine fibroma and pelvic inflammatory disease [8,19].
Moreover, HE4 levels in healthy women are affected by
age, BMI and smoking [39].In our study CA125 and HE4 yielded a sensitivity of
90% and 87% and a specificity of 70% and 100% respect-
ively in the diagnosis of epithelial ovarian cancer. HE4
never increased in women with endometriosis and it was
able to correctly discriminate malignant from all benign
ovarian masses. Therefore we agree with previous re-
ports that HE4 is the most useful marker for the differ-
ential diagnosis between EOC and ovarian endometriosis
[19]. However, since some benign conditions can be asso-
ciated with high HE4 levels, in selected cases CA72-4 may
be useful for the differential diagnosis. Nevertheless the
role of CA72-4 in the differential diagnosis between benign
form malignant ovarian mass is still controversial [18].
In our study a slight and not statistically significant in-
crease of CA72-4 was found in a small number of patients
with endometriosis, with the highest observed value of 6.2
U/mL, which is indeed a borderline value, found only in
one woman. Our data confirm the results reported by
Lenhard et al. who showed that CA125 but not CA72-4
tends to be increased in the presence of endometriosis
[24]. A multimarker approach, consisting of HE4, CA125
and CA72-4, can provide a more accurate tool for a differ-
ential diagnosis of patients with ovarian endometriotic
cysts, other benign ovarian masses and ovarian cancer.
Conclusions
In conclusion our results suggest that the use of serum
HE4, CA125 and CA72-4 may be a valuable approach
for distinguishing patients with ovarian endometrioma
or other benign adnexal masses from those with ovarian
malignancy. This approach could reduce medical costs
related to more expensive diagnostic procedures and it
may have a reassuring effect on the patient. Further
studies are needed to confirm these results.
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